Dearborn Partners LLC Sells 4,731 Shares of Stryker Co. (NYSE:SYK)

Dearborn Partners LLC reduced its holdings in Stryker Co. (NYSE:SYK) by 4.3% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 106,067 shares of the medical technology company’s stock after selling 4,731 shares during the period. Stryker accounts for approximately 1.6% of Dearborn Partners LLC’s portfolio, making the stock its 24th largest position. Dearborn Partners LLC’s holdings in Stryker were worth $38,318,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. International Assets Investment Management LLC grew its position in Stryker by 66,967.5% in the 3rd quarter. International Assets Investment Management LLC now owns 853,769 shares of the medical technology company’s stock worth $308,433,000 after purchasing an additional 852,496 shares during the last quarter. JPMorgan Chase & Co. grew its position in Stryker by 10.4% during the first quarter. JPMorgan Chase & Co. now owns 8,651,403 shares of the medical technology company’s stock worth $3,096,078,000 after buying an additional 813,311 shares in the last quarter. 1832 Asset Management L.P. increased its stake in Stryker by 146.9% during the first quarter. 1832 Asset Management L.P. now owns 878,669 shares of the medical technology company’s stock valued at $314,449,000 after acquiring an additional 522,817 shares during the period. American Century Companies Inc. raised its holdings in Stryker by 287.6% in the 2nd quarter. American Century Companies Inc. now owns 505,608 shares of the medical technology company’s stock valued at $172,033,000 after acquiring an additional 375,166 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Stryker by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 31,459,393 shares of the medical technology company’s stock worth $11,258,373,000 after purchasing an additional 309,592 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Down 1.3 %

Shares of SYK opened at $383.28 on Friday. The stock’s fifty day simple moving average is $362.94 and its 200-day simple moving average is $346.72. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $146.11 billion, a PE ratio of 41.08, a price-to-earnings-growth ratio of 2.93 and a beta of 0.91. Stryker Co. has a 12-month low of $282.35 and a 12-month high of $392.70.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. The firm had revenue of $5.49 billion for the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period last year, the firm earned $2.46 earnings per share. As a group, research analysts predict that Stryker Co. will post 12.06 earnings per share for the current year.

Analyst Ratings Changes

SYK has been the subject of several research reports. Wells Fargo & Company raised their target price on Stryker from $381.00 to $405.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. BTIG Research lifted their target price on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Royal Bank of Canada increased their price target on shares of Stryker from $386.00 to $400.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Evercore ISI lifted their price objective on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Finally, Barclays increased their target price on Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a report on Thursday, October 31st. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average price target of $393.65.

Insider Buying and Selling

In related news, VP M Kathryn Fink sold 7,347 shares of the company’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the transaction, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. This represents a 42.25 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 67,381 shares of company stock valued at $24,825,275 in the last 90 days. 5.90% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.